Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Rubio MG, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Buti M, et al. Among authors: calleja jl. PLoS One. 2018 Jun 25;13(6):e0199926. doi: 10.1371/journal.pone.0199926. eCollection 2018. PLoS One. 2018. PMID: 29940039 Free PMC article.
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities.
Buti M, Morillas RM, Pérez J, Prieto M, Solà R, Palau A, Diago M, Bonet L, Gallego A, García-Samaniego J, Testillano M, Rodríguez M, Castellano G, Gutiérrez ML, Delgado M, Mas A, Romero-Gómez M, Calleja JL, González-Guirado A, Arenas JI, García-Buey L, Andrade R, Gila A; ORIENTE-2 study group. Buti M, et al. Among authors: calleja jl. Eur J Gastroenterol Hepatol. 2015 Jan;27(1):46-54. doi: 10.1097/MEG.0000000000000195. Eur J Gastroenterol Hepatol. 2015. PMID: 25341057
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG, Crespo J, Piqueras B, Pascasio JM, Comas C, Gutierrez ML, Aguirre A, Suárez E, García-Samaniego J, Rivero M, Acero D, Fernandez-Bermejo M, Moreno D, Sánchez-Pobre P, de Cuenca B, Moreno-Palomares JJ, Esteban R, Buti M. Riveiro-Barciela M, et al. Among authors: calleja jl. Dig Dis Sci. 2017 Mar;62(3):784-793. doi: 10.1007/s10620-017-4448-7. Epub 2017 Jan 11. Dig Dis Sci. 2017. PMID: 28078526
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Buti M, et al. Among authors: calleja jl. PLoS One. 2017 Sep 12;12(9):e0184550. doi: 10.1371/journal.pone.0184550. eCollection 2017. PLoS One. 2017. PMID: 28898281 Free PMC article. Clinical Trial.
Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH).
Calleja JL, Macias J, Forns X, Garcia F, Berenguer M, Garcia Deltoro M, Buti M, Granados R, Carrion JA, Morano L, Fernandez I, Coste P, Pineda JA. Calleja JL, et al. Gastroenterol Hepatol. 2018 Nov;41(9):597-608. doi: 10.1016/j.gastrohep.2018.07.010. Epub 2018 Sep 27. Gastroenterol Hepatol. 2018. PMID: 30270150 English, Spanish. No abstract available.
Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.
Suárez E, Buti M, Rodríguez M, Prieto M, Pascasio-Acevedo JM, Casanovas T, Crespo J, Tapiador JAR, Gómez-Rodríguez R, Figueruela B, Diago M, Morillas RM, Zozaya JM, Calleja JL, Casado M, Molina E, Fuentes J, Simón MA. Suárez E, et al. Among authors: calleja jl. Eur J Gastroenterol Hepatol. 2019 Feb;31(2):267-271. doi: 10.1097/MEG.0000000000001289. Eur J Gastroenterol Hepatol. 2019. PMID: 30576297
The path to successful hepatitis C elimination in Spain.
Crespo J, Cabezas J, Calleja JL, Buti M, Lazarus JV. Crespo J, et al. Among authors: calleja jl. Nat Rev Gastroenterol Hepatol. 2023 Nov;20(11):689-690. doi: 10.1038/s41575-023-00813-z. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37500899 No abstract available.
Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Rodríguez-Nóvoa S, García-Samaniego J, Prieto M, Calleja JL, Pascasio JM, Delgado Blanco M, Crespo J, Buti M, Bonet Vidal ML, Arenas Ruiz Tapiador J, Fernández-Rodríguez C, Solá R, Fraga E, González Diéguez L, Núñez O, Praga M, Del Pino-Montes J, Romero-Gómez M, Morillas R, Diago M, Castro Á; MENTE Study Group. Rodríguez-Nóvoa S, et al. Among authors: calleja jl. J Clin Gastroenterol. 2016 Oct;50(9):779-89. doi: 10.1097/MCG.0000000000000569. J Clin Gastroenterol. 2016. PMID: 27332746
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4.
Mariño Z, Pascasio-Acevedo JM, Gallego A, Diago M, Baliellas C, Morillas R, Prieto M, Moreno JM, Sánchez-Antolín G, Vergara M, Forné M, Fernández I, Castro MA, Pascual S, Gómez A, Castells L, Montero JL, Crespo J, Calleja JL, García-Samaniego J, Carrión JA, Arencibia AC, Blasco A, López-Núñez C, Sánchez-Ruano JJ, Gea-Rodríguez F, Giráldez Á, Cabezas J, Hontangas V, Torras X, Castellote J, Romero-Gómez M, Turnes J, de Artaza T, Narváez I, Cuervas-Mons V, Forns X. Mariño Z, et al. Among authors: calleja jl. Liver Int. 2017 Dec;37(12):1823-1832. doi: 10.1111/liv.13470. Epub 2017 Jun 5. Liver Int. 2017. PMID: 28481460
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J. Villanueva C, et al. Among authors: calleja jl. Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22. Lancet. 2019. PMID: 30910320 Clinical Trial.
265 results